This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News For Sep 26, 2018
by Zacks Equity Research
Companies in the news are: FDS, SONC, AZN and EVHC
Is Envision Healthcare (EVHC) a Suitable Value Stock Now?
by Zacks Equity Research
Let's see if Envision Healthcare Corporation (EVHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
EVHC vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EVHC vs. USPH: Which Stock Is the Better Value Option?
Is Envision Healthcare (EVHC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
EVHC vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
EVHC vs. USPH: Which Stock Is the Better Value Option?
Is Envision Healthcare (EVHC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Envision Healthcare (EVHC) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Envision Healthcare (EVHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Envision Healthcare (EVHC) Q2 earnings were backed by higher contribution from its segments.
Envision Healthcare (EVHC) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Envision Healthcare (EVHC) delivered earnings and revenue surprises of 4.55% and -1.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stocks Earnings Due on Aug 6: EVHC, THC, BKD
by Zacks Equity Research
Increased demand for healthcare products and service partly offset by reduced admissions and high costs are likely to affect Q2 earnings of healthcare industry.
Envision Healthcare (EVHC) Q2 Earnings: What's in Store?
by Zacks Equity Research
Envision Healthcare (EVHC) Q2 earnings should gain from higher revenues from thePhysician Service segment and gains from cost control initiatives.
EVHC vs. ADUS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EVHC vs. ADUS: Which Stock Is the Better Value Option?
Envision Healthcare to Go Private With Acquisition by KKR
by Zacks Equity Research
Envision Healthcare to become a private company on acquisition by private equity company KKR.
Envision Healthcare's (EVHC) Ratings on Review for Downgrade
by Zacks Equity Research
Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.
Implied Volatility Surging for Envision Healthcare (EVHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Envision Healthcare (EVHC) stock based on the movements in the options market lately.
Envision Healthcare (EVHC) Up 15.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Envision Healthcare (EVHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Envision Healthcare Corporation (EVHC)
by Zacks Equity Research
Moving Average Crossover Alert: Envision Healthcare Corporation (EVHC)
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Envision Healthcare (EVHC) Q1 Earnings Beat, Revenues Rise
by Zacks Equity Research
Envision Healthcare's (EVHC) Q1 earnings gain from by revenue growth at its Physicians Services segment.
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
3 Healthcare Stocks Set to Beat Q1 Earnings Estimates
by Zacks Equity Research
Elevated flu activity, aging population, high expenses, and a low tax rate would influence healthcare stocks' earnings in Q1.
Healthcare Stocks' Earnings Due on May 7: EVHC, PINC & More
by Zacks Equity Research
Acute flu, aging population, increase in patient volumes and high claims would affect healthcare companies' Q1 earnings.
Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up?
by Zacks Equity Research
Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.
Will Cigna (CI) Beat Q1 Earnings Estimates This Time Again?
by Zacks Equity Research
Cigna (CI) Q1 earnings to see upside from higher revenues, enrollment growth.
3 Reasons Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.